Tag:
Mark Hermelin
Latest Headlines
Latest Headlines
Fed up investors sue KV over Makena projections
KV Pharmaceutical ( $KV.A ) investors aren't happy. The company's stock has fallen into the toilet, down to $1 per share from $6.50 in mid-February. Some of that decline is no doubt the consequence of
